dr. rugo discusses the regulatory process behind biosimilars
Published 5 years ago • 97 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:43
dr. rugo discusses the equivalency of trastuzumab biosimilars
-
2:00
dr. rugo discusses advancements with biosimilars
-
2:17
dr. kolberg explains the approval process for biosimilars
-
1:35
dr. rugo on the optimal setting for biosimilar evaluation
-
1:53
dr. rugo discusses a comparative review of trastuzumab biosimilars
-
0:59
dr. verma discusses the approval process for biosimilars
-
2:52
how biologic medicines are made | how it's made
-
5:42
materia medica: digitalis
-
3:00
biosimilars: complex copycat drugs
-
1:39
dr. rugo on anti-angiogenesis therapy response predictors
-
1:15
dr. rugo discusses the future of angiogenesis in breast cancer
-
0:59
dr. hope rugo on safety of trastuzumab biosimilar for her2 breast cancer
-
0:56
dr. rugo on proliferation as an anti-angiogenesis marker
-
32:37
biologics, biosimilars, and the two-fold u.s. approval framework’s possible impact on prices
-
14:19
regulatory pathway for biosimilars
-
5:58
the availability of multiple biosimilars for 1 biologic
-
7:22
an overview of biosimilarity
-
3:45
what are biosimilars? how do they work for arthritis?
-
1:40
dr. pegram on the manufacturing process of biosimilars
-
1:55
dr. hurvitz on the fda approval process for biosimilars
-
1:30
dr. hope rugo on trastuzumab biosimilar in her2-positive breast cancer
-
1:36
dr. rugo on the efficacy of bevacizumab in breast cancer